Journal of General Virology, Vol 78, 917-923, Copyright © 1997 by Society for General Microbiology

ARTICLES

Serological and T-helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls

JC Luxton, RC Rose, T Coletart, P Wilson and PS Shepherd
Department of Immunology, Guy's Hospital Medical School, UMDS, London, UK.

In a cross-sectional study we have investigated serological and T- helper (Th) cell responses to human papillomavirus type 16 (HPV-16) L1 in women with HPV-16 related diseases and related them to cervical histology and HPV DNA status. Using a virus-like particle (VLP) based ELISA to detect antibodies to the HPV-16 L1 capsid protein, 45% (33/73) of women with cervical dysplasia, 40% (2/5) of women with cervical cancer, 36% (4/11) of healthy adult female controls and 6% (2/35) of healthy children were found to be seropositive. Amongst women with cervical dysplasia, the highest levels of seropositivity were found in those who were HPV-16 DNA positive (60%, 15/25) or positive for any of the "high-risk' HPV types, 16/18/33 (58%, 18/31), when compared with those with HPV type "X' (25%, 5/20) or with healthy children (6%, 2/35; P < 0.05 for all comparisons). There was a trend for women with cervical dysplasia to show an increased level of seropositivity with increasing grade of lesion. There was no direct correlation found between seropositivity and Th cell responses in all groups studied. However, a combined analysis of each individual's Th and B cell responses suggests that a Th1 pattern of response is predominant amongst healthy adult controls (80% of responders) but reduced in women with cervical dysplasia (55% of responders). A trend towards a decrease in Th1 type responses was also noted with increasing grade of dysplastic lesion. These findings provide further evidence for the importance of the Th response in the control of genital HPV infections.

This article has been cited by other articles:

				I. B. Villada, M. M. Barracco, M. Ziol, A. Chaboissier, N. Barget, S. Berville, B. Paniel, E. Jullian, T. Clerici, B. Maillere, et al. Spontaneous Regression of Grade 3 Vulvar Intraepithelial Neoplasia Associated with Human Papillomavirus-16-Specific CD4+ and CD8+ T-Cell Responses Cancer Res., December 1, 2004; 64(23): 8761 - 8766. [Abstract] [Full Text] [PDF]

				M. Engelmark, A. Beskow, J. Magnusson, H. Erlich, and U. Gyllensten Affected sib-pair analysis of the contribution of HLA class I and class II loci to development of cervical cancer Hum. Mol. Genet., September 1, 2004; 13(17): 1951 - 1958. [Abstract] [Full Text] [PDF]

				J. C. Luxton, R. Nath, N. Derias, A. Herbert, and P. S. Shepherd Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment J. Gen. Virol., May 1, 2003; 84(5): 1063 - 1070. [Abstract] [Full Text] [PDF]

				M. Nakagawa, R. Viscidi, I. Deshmukh, M. D. Costa, J. M. Palefsky, S. Farhat, and A.-B. Moscicki Time Course of Humoral and Cell-Mediated Immune Responses to Human Papillomavirus Type 16 in Infected Women Clin. Vaccine Immunol., July 1, 2002; 9(4): 877 - 882. [Abstract] [Full Text] [PDF]

				M. Scott, M. Nakagawa, and A.-B. Moscicki Cell-Mediated Immune Response to Human Papillomavirus Infection Clin. Vaccine Immunol., March 1, 2001; 8(2): 209 - 220. [Full Text] [PDF]

				Y. Sun, J. Eluf-Neto, F. X. Bosch, N. Muñoz, J. M. M. Walboomers, C. J. L. M. Meijer, K. V. Shah, B. Clayman, and R. P. Viscidi Serum Antibodies to Human Papillomavirus 16 Proteins in Women from Brazil with Invasive Cervical Carcinoma Cancer Epidemiol. Biomarkers Prev., October 1, 1999; 8(10): 935 - 940. [Abstract] [Full Text]

				T. de Gruijl, H. Bontkes, J. Walboomers, P Coursaget, M. Stukart, C Dupuy, E Kueter, R. Verheijen, T. Helmerhorst, M. Duggan-Keen, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome J. Gen. Virol., February 1, 1999; 80(2): 399 - 408. [Abstract]